8-K: Boston Scientific Secures $2 Billion in Debt Financing to Fund Axonics Acquisition

Boston Scientific's finance subsidiary has successfully priced a $2 billion offering of senior notes to help fund the acquisition of Axonics, Inc.

Summary

• Boston Scientific Corporation, through its finance subsidiary American Medical Systems Europe B.V., has priced a public offering of senior notes totaling 2 billion euros.
• The offering includes 750 million euros of 3.375% senior notes due in 2029 and 1.25 billion euros of 3.500% senior notes due in 2032.
• The notes are fully and unconditionally guaranteed by Boston Scientific Corporation.
• The net proceeds from the offering are approximately 1.980 billion euros after deducting underwriting discounts and expenses.
• The company intends to use the proceeds, along with other funds, to finance the acquisition of Axonics, Inc., pay related fees, and potentially repay existing debt.
• If the Axonics acquisition is not completed by a specified date, the notes will be subject to a special mandatory redemption at 101% of their principal amount.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company successfully raised a significant amount of capital for a strategic acquisition. The terms of the debt are reasonable, and the company has a clear plan for the use of proceeds. However, there are some risks associated with the acquisition and the debt obligations.

Positives

• The successful pricing of the senior notes provides significant capital for the Axonics acquisition.
• The offering allows Boston Scientific to secure funding at fixed interest rates.
• The notes are fully guaranteed by Boston Scientific, enhancing investor confidence.
• The company has flexibility to use any remaining funds for debt repayment or general corporate purposes.

Negatives

• The company will incur additional debt obligations with the issuance of these notes.
• The special mandatory redemption clause could result in additional costs if the Axonics acquisition is not completed.

Risks

• The Axonics acquisition may not be completed by the specified deadline, triggering the special mandatory redemption.
• The company's ability to integrate Axonics successfully could impact the overall financial performance.
• Changes in market conditions could affect the company's ability to refinance or service the debt.
• The company is exposed to interest rate risk, although the notes are at fixed rates, future debt may not be.

Future Outlook

The company intends to use the net proceeds from the offering, along with other funds, to finance the acquisition of Axonics, Inc., pay related fees, and potentially repay existing debt. The company may also use the funds for general corporate purposes.

Management Comments

• The company intends to use the net proceeds from the offering, together with borrowings under its commercial paper program and cash on hand, to finance the purchase price of the Companys previously announced agreement to acquire Axonics, Inc. and to pay related fees and expenses and, to the extent that the net proceeds from the offering of the Notes are not used for such purposes, to fund the repayment at maturity of the Companys 3.450% senior notes due March 2024 and to pay accrued and unpaid interest with respect to such notes, and for general corporate purposes.

Industry Context

This debt offering is a common strategy for large medical device companies to finance acquisitions and manage their capital structure. The acquisition of Axonics is likely aimed at expanding Boston Scientific's portfolio in a specific therapeutic area, which is a typical growth strategy in the medical technology industry.

Comparison to Industry Standards

• The interest rates on the senior notes are within the typical range for investment-grade corporate debt at the time of issuance.
• The use of a finance subsidiary for the issuance is a common practice for multinational corporations to optimize their capital structure.
• The special mandatory redemption clause is a standard provision in debt offerings related to acquisitions, providing a level of protection for investors.
• Comparable companies such as Medtronic and Abbott have also used debt financing to fund acquisitions and manage their capital structure.

Stakeholder Impact

• Shareholders will be impacted by the increased debt and the potential for growth through the Axonics acquisition.
• Employees may experience changes due to the integration of Axonics.
• Customers may benefit from the expanded product portfolio and services.
• Creditors will be impacted by the new debt obligations.

Next Steps

• The company will complete the acquisition of Axonics, Inc.
• The company will repay its 3.450% senior notes due March 2024.
• The company will manage its debt obligations and monitor market conditions.

Key Dates

Keywords

senior notes, debt financing, Axonics acquisition, Boston Scientific, bond offering, capital raise, medical devices, corporate finance